Wuttke Wolfgang, Gorkow Christoph, Seidlová-Wuttke Dana
Division of Clinical and Experimental Endocrinology, Department of Obstetrics and Gynaecology, University of Göttingen, Germany.
Menopause. 2006 Mar-Apr;13(2):185-96. doi: 10.1097/01.gme.0000174470.44822.57.
In this study, the effects of the Cimicifuga racemosa (CR) preparation CR BNO 1055 on markers of bone metabolism, hormones, sex hormone-binding globulin (SHBG), lipometabolism, vaginal maturity, and routine laboratory parameters were compared with those of conjugated estrogens (CE) and placebo.
Sixty-two postmenopausal women were included in this double-blind study. Treatment duration with CR (daily dose corresponds to 40 mg of herbal drug), CE (0.6 mg/day), or placebo was 12 weeks. Markers of bone turnover (bone-specific alkaline phosphatase, CrossLaps), estradiol, follicle-stimulating hormone, leuteinizing hormone, SHBG, triglycerides, total cholesterol, high-density cholesterol, low-density cholesterol, and routine clinical chemistry parameters were determined from blood samples. Vaginal "maturity index" was determined from vaginal smears.
The analyses of bone turnover markers indicated beneficial effects for CR and CE on bone metabolism. CR stimulated osteoblast activity, whereas CE inhibited osteoclast activity. Whereas CE showed strong estrogenic effects on vaginal mucosa, CR showed weak estrogen-like activity. No significant effects were seen on coagulation markers and liver enzymes in the blood. CR was well tolerated.
These results suggest that CR has beneficial bone remodeling and weak estrogen-like effects in the vaginal mucosa.
在本研究中，将总状升麻（CR）制剂CR BNO 1055对骨代谢标志物、激素、性激素结合球蛋白（SHBG）、脂质代谢、阴道成熟度及常规实验室参数的影响与共轭雌激素（CE）和安慰剂进行比较。
62名绝经后女性纳入本双盲研究。CR（每日剂量相当于40mg草药）、CE（0.6mg/天）或安慰剂的治疗持续时间为12周。从血样中测定骨转换标志物（骨特异性碱性磷酸酶、交联C端肽）、雌二醇、促卵泡激素、促黄体生成素、SHBG、甘油三酯、总胆固醇、高密度胆固醇、低密度胆固醇及常规临床化学参数。从阴道涂片测定阴道“成熟指数”。
骨转换标志物分析表明，CR和CE对骨代谢有有益作用。CR刺激成骨细胞活性，而CE抑制破骨细胞活性。CE对阴道黏膜显示出强烈的雌激素作用，而CR显示出较弱的雌激素样活性。对血液中的凝血标志物和肝酶未见显著影响。CR耐受性良好。
这些结果表明，CR在阴道黏膜中具有有益的骨重塑作用和较弱的雌激素样作用。
